RNA pulsed dendritic cells: an approach for cancer immunotherapy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Vaccine

• Publication date

  2013-02-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2012.12.027PMID 23306369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient

  2012cited by this paper
• Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

  2012cited by this paper
• Harnessing human plasmacytoid dendritic cells as professional APCs

  2012cited by this paper
• Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.

  2012cited by this paper
• Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

  2012cited by this paper
• hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

  2011cited by this paper
• Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

  2011cited by this paper
• mRNA: delivering an antitumor message?

  2011cited by this paper
• Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

  2011cited by this paper
• FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

  2011cited by this paper
• mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells.

  2011cited by this paper
• Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

  2011cited by this paper
• Tumor vaccination using messenger RNA: prospects of a future therapy.

  2011cited by this paper
• Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

  2011cited by this paper
• Comparative Analysis of Cytotoxic T Lymphocyte Response Induced by Dendritic Cells Loaded with Hepatocellular Carcinoma -Derived RNA or Cell Lysate

  2010cited by this paper
• RNA as performance-enhancers for dendritic cells

  2010cited by this paper
• Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

  2010cited by this paper
• Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design

  2010cited by this paper
• CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals.

  2010cited by this paper
• Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

  2010cited by this paper
• Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

  2010cited by this paper
• Attenuated Expression of A20 Markedly Increases the Efficacy of Double-Stranded RNA-Activated Dendritic Cells As an Anti-Cancer Vaccine1

  2009cited by this paper
• Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

  2009cited by this paper
• Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients

  2009cited by this paper
• Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

  2009cited by this paper
• Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

  2008cited by this paper
• Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

  2008cited by this paper
• T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

  2007cited by this paper
• Tolerogenic dendritic cells and the quest for transplant tolerance

  2007cited by this paper
• Cancer stem cells.

  2006cited by this paper
• Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA

  2006cited by this paper
• Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

  2006cited by this paper
• Tumor-driven evolution of immunosuppressive networks during malignant progression.

  2006cited by this paper
• Results of a phase I study utilizing monocyte‐derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma

  2005cited by this paper
• Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

  2005cited by this paper
• Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

  2005cited by this paper
• Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1

  2005cited by this paper
• A critical function for type I interferons in cancer immunoediting

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

  2005cited by this paper
• mRNA Is an Endogenous Ligand for Toll-like Receptor 3*

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• Messenger RNA-based vaccines

  2004cited by this paper
• Heterogeneity of the Y Chromosome in Afro-Brazilian Populations

  2004cited by this paper
• Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

  2004cited by this paper
• Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

  2003cited by this paper
• Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

  2003cited by this paper
• Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation.

  2003cited by this paper
• Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

  2003cited by this paper
• Historical genetics: Spatiotemporal analysis of the formation of the Brazilian population

  2003cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• Interferon‐α disables dendritic cell precursors: dendritic cells derived from interferon‐α‐treated monocytes are defective in maturation and T‐cell stimulation

  2003cited by this paper
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.

  2002cited by this paper
• Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

  2002cited by this paper
• Efficient genetic modification of murine dendritic cells by electroporation with mRNA

  2002cited by this paper
• Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

  2002cited by this paper
• Dendritic cells as vectors for therapy.

  2001cited by this paper
• Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1

  2001cited by this paper
• Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.

  2001cited by this paper
• Progress in human tumour immunology and immunotherapy

  2001cited by this paper
• Dendritic cells: specialized and regulated antigen processing machines.

  2001cited by this paper
• In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

  2000cited by this paper
• Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

  2000cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.

  2000cited by this paper
• Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA.

  2000cited by this paper
• In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies

  2000cited by this paper
• Dendritic cells in cancer immunotherapy.

  2000cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

  1999cited by this paper
• Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines.

  1999cited by this paper
• Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease

  1999cited by this paper
• IL-10 transgenic mice present a defect in T cell development reminiscent of SCID patients.

  1999cited by this paper
• Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells.

  1999cited by this paper
• Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

  1999cited by this paper
• DNA and RNA-based vaccines: principles, progress and prospects.

  1999cited by this paper
• Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.

  1999cited by this paper
• Cancer therapy using a self-replicating RNA vaccine

  1999cited by this paper
• The makings of a tumor rejection antigen.

  1999cited by this paper
• Ex vivo expansion of hematopoietic progenitor cells for clinical use.

  1998cited by this paper
• Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

  1998cited by this paper
• Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes

  1998cited by this paper
• Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages

  1998cited by this paper
• Tumor immunology: the glass is half full.

  1998cited by this paper
• Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance

  1997cited by this paper
• Developmental regulation of MHC class II transport in mouse dendritic cells

  1997cited by this paper
• Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells

  1997cited by this paper
• Interleukin‐10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin‐4 and granulocyte/ macrophage‐colony‐stimulating factor

  1997cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Escape from host-antitumor immunity.

  1997cited by this paper
• Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

  1996cited by this paper
• High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med 1996 Oct 1;184(4):following 1590]

  1996cited by this paper

• Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity.

  2023cites this paper
• From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases

  2021cites this paper
• Development of neoantigens: from identification in cancer cells to application in cancer vaccines

  2021cites this paper
• Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target

  2020cites this paper
• Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells

  2020cites this paper
• Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment

  2019cites this paper
• RNA-loaded dendritic cells: more than a tour de force in cancer therapeutics.

  2019cites this paper
• Checkpoints and beyond - Immunotherapy in colorectal cancer.

  2019cites this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cites this paper
• Oral Pathobiont Activates Anti-Apoptotic Pathway, Promoting both Immune Suppression and Oncogenic Cell Proliferation

  2018cites this paper
• Classification of current anticancer immunotherapies

  2017cites this paper
• Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma

  2017cites this paper
• Human IDO-competent, long-lived immunoregulatory dendritic cells induced by intracellular pathogen, and their fate in humanized mice

  2017cites this paper
• A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma

  2017cites this paper
• Trial watch: Dendritic cell-based anticancer immunotherapy

  2017cites this paper
• Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity

  2016cites this paper
• Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM‐ALK)‐reactive CD8+ T cell responses in children with NPM‐ALK+ anaplastic large cell lymphoma

  2016cites this paper
• Anti-tumor immunity induced by a novel nanoparticulate vaccine : a mechanistic approach

  2016cites this paper
• Optimizing the process of nucleofection for professional antigen presenting cells

  2015cites this paper
• Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines.

  2015cites this paper
• Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell

  2015cites this paper
• Dendritic Cell Targets for Self-Replicating RNA Vaccines

  2015influential citation
• A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype

  2015cites this paper
• Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity

  2015cites this paper
• Inmunoterapia en melanoma: vacunas de células dendríticas

  2015cites this paper
• Classification of current anticancer immunotherapies

  2014cites this paper
• EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model.

  2014cites this paper
• miRNA regulates the differentiation,maturation and function of dendritic cells

  2014cites this paper
• Evaluating the role of low-speed centrifugation towards transfecting human peripheral blood mononuclear cell culture.

  2014cites this paper
• Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro.

  2014influential citation
• Trial watch: Dendritic cell-based anticancer therapy

  2014cites this paper
• Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

  2014cites this paper